Kassa Ayalew, MD

Articles by Kassa Ayalew, MD

Romiplostim for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura

ByFaranak Jamali, MD,Steven Lemery, MD,Kassa Ayalew, MD,Suzanne Robottom, MD,Kathy Robie-suh, MD, PhD,Dwaine Rieves, MD,Richard Pazdur, MD

On August 22, 2008, the US Food and Drug Administration (FDA) granted marketing approval (licensure) to romiplostim (Nplate, Amgen Inc) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

Latest Updated Articles